ClinicalTrials.gg
Active, not recruitingNCT05066503Updated Nov 9, 2026

Nutritional Therapy for Delirium in Elderly Hospitalized Subjects

An interventional study of 260279 active study product in Subacute Delirium, sponsored by University of Arkansas. Active, not recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Arkansas · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2020, registered Sep 2021).
Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 263 studies in Delirium with a site in United States — 37 open to participants now, 60 under way, 7 of them phase 3. Delirium · United States.

Planned enrollment
108th of 194
60 · median 84
Started
2020
with 9 others
No phase
105 of 263
20 open now
Primary completion
2027-06
later than 40 of 59 live
Registered
201st of 263
by date

Among the 263 studies in Delirium with a site in United States, this one is the 108th largest by planned enrollment of the 194 interventional ones that give a count, is one of 10 that started in 2020, is one of 105 with no phase, reaches primary completion later than 40 of the 59 other live ones, and was the 201st registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

37 of the 263 studies in Delirium with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 263 studies in Delirium with a site in United States, or all of them as a file.
02

Study summary

The investigators have developed a proprietary blend of amino acids that they think will help to prevent or reduce the severity of delirium in older adults (60 years and older) who are hospitalized for certain infections. In this study, up to 60 people will be enrolled.20 will be asked to drink this blend twice a day for up to 4 days, and 20 will receive standard treatment in the hospital for the same time period. The other 20 subjects will be non-delirious control subjects who do not consume any study products.

Read the detailed description

This will be an interventional pilot study to determine the effectiveness of a specific amino acid supplement developed by the investigators versus standard treatment in mitigating delirium in geriatric patients hospitalized at UAMS for certain infections. Up to 40 delirious and 20 non-delirious subjects (Aged 60 years and older) of any gender or ethnicity will be enrolled (60 subjects maximum). Twenty patients with delirium will be asked to drink this blend twice a day for up to 4 days, and 20 patients with delirium will receive standard treatment in the hospital for the same time period. The other 20 subjects will be non-delirious control subjects who do not consume any study products. All subjects will undergo 2-5 blood draws and 3-7 cognitive assessments while they are admitted to the hospital, depending on study group assignment and discharge date.

03

Conditions studied

  • Subacute Delirium

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Delirious cohort

  1. Aged 60 years and older.
  2. Documented presence of either delirium, acute confusion, or altered mental status in medical record.
  3. Currently hospitalized with a diagnosis of one of the following:

    1. sepsis/septicemia
    2. Pneumonia
    3. Urinary tract infection
    4. Clostridium-difficile infection
    5. Other bone or tissue infection
    6. Fever of unknown origin

Inclusion Criteria: NON-Delirious cohort

  1. Aged 60 years and older.
  2. Current diagnosis of one of the following:

    1. sepsis/septicemia
    2. Pneumonia
    3. Urinary tract infection
    4. Clostridium-difficile infection
    5. Other bone or tissue infection
    6. Fever of unknown origin

Exclusion Criteria: all subjects

  1. Chronic kidney disease ( \<30).
  2. Admitted to the hospital for major psychiatric illness.
  3. Major psychiatric illness not controlled by medication/treatment.
  4. Delirium etiology of drug overdose or alcohol withdrawal.
  5. Major surgery within the past five days.
  6. Known or suspected Covid-19 positive.
  7. Continuous feeding tube
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Delirious subjects receiving active study product

    Subjects will ingest an oral amino-acid containing nutritional supplement twice daily for up to 4 days.

    Dietary Supplement: 260279 active study product

  • No intervention
    Control group

    Delirious control group and non-delirious control group who receives standard treatment in the hospital.

Interventions

  • Dietary supplement260279 active study product

    The active study product (20g per serving) contains 13.6g of amino acids and natural flavors, citric acid, malic acid, and stevia for flavoring.

    Also known as: there is not a non-proprietary name for this supplement.

06

What researchers measure

Primary outcomes

  1. Change in CAM-S (Confusion Assessment Method-Short) and 4 AT score from baseline to day 3 or up to day 4.

    CAM-S and 4 AT is a tool to determine and quantify delirium. Subjects in the non-control arms will undergo this test twice each day. The score ranges from 0-7, with lower numbers being better (little to no signs of delirium).

    Time frame: As determined over an up to 4-day intervention duration.

07

Study locations

1 site
  • UAMS Center on Aging
    Little Rock, Arkansas 72205, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Jun 2027, 79 months after the start.

Of 219 non-industry interventional studies with no phase under Delirium, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 79 months is above that.

Counting every sponsor, half of 222 studies reached it within 26 months; a quarter within 12 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Sep 2026 → Jun 2027 and completion Jan 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Oct 4, 2021
StartActual
Nov 16, 2020
Primary completionEst.
Jun 2027was Sep 2026
CompletionEst.
Dec 2027was Jan 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Jun 2027
Nov 9, 2026
Study completion
Jan 2027→Dec 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Sep 2026→Jun 2027
    Study completion Jan 2027→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05066503
Responsible party
Sponsor
First posted
Oct 4, 2021
Start date
Nov 16, 2020
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Gohar Azhar, M.D.
principal investigator · University of Arkansas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion